{"id":5831,"date":"2021-05-25T08:20:00","date_gmt":"2021-05-25T08:20:00","guid":{"rendered":"https:\/\/irlab.se\/irlabs-lakemedelskandidat-mesdopetams-fas-i-resultat-publicerade-i-vetenskapliga-tidskriften-prp\/"},"modified":"2021-05-25T08:20:00","modified_gmt":"2021-05-25T08:20:00","slug":"irlabs-lakemedelskandidat-mesdopetams-fas-i-resultat-publicerade-i-vetenskapliga-tidskriften-prp","status":"publish","type":"post","link":"https:\/\/irlab.se\/sv\/irlabs-lakemedelskandidat-mesdopetams-fas-i-resultat-publicerade-i-vetenskapliga-tidskriften-prp\/","title":{"rendered":"IRLAB:s l\u00e4kemedelskandidat mesdopetams Fas I- resultat publicerade i vetenskapliga tidskriften PR&amp;P"},"content":{"rendered":"<p><span><span><span>Den vetenskapliga artikeln beskriver den prospektiva, singel-center, randomiserade, dubbelblinda, placebokontrollerade Fas I- first-in-human (FIH)-studien med mesdopetam. Studien utv&auml;rderade s&auml;kerhet, tolerabilitet och farmakokinetik f&ouml;r eskalerande singeldoser och multipla doser av mesdopetam. Slutsatsen var att mesdopetam var s&auml;kert och tolererades v&auml;l hos friska manliga frivilliga f&ouml;rs&ouml;kspersoner. Farmakokinetisk analys visade p&aring; snabb absorption och doslinj&auml;r farmakokinetik f&ouml;r mesdopetam vid enstaka och vid upprepade doser. Farmakokinetiken f&ouml;r mesdopetam st&ouml;der anv&auml;ndning tv&aring; g&aring;nger dagligen f&ouml;r patienter.<\/span><\/span><\/span><\/p>\n<p><span><span><span>&rdquo;Den publicerade artikeln f&ouml;r mesdopetams Fas I-studie st&auml;rker det v&auml;xande vetenskapliga st&ouml;det f&ouml;r l&auml;kemedelskandidatens betydande potential vid Parkinsons sjukdom. Publicering av PR&amp;P g&ouml;r det m&ouml;jligt f&ouml;r v&aring;ra studieresultat att n&aring; en bred publik&rdquo;, s&auml;ger Susanna Waters, MD och Ph.D., Director of Biology &amp; Biostatistics p&aring; IRLAB.<\/span><\/span><\/span><\/p>\n<p><span><span><span>Tidskriften <em>Pharmacology Research &amp; Perspectives<\/em> (PR&amp;P) publiceras gemensamt av <em>American Society for Pharmacology and Experimental Therapeutics<\/em> (ASPET), <em>British Pharmacological Society<\/em> (BPS) och Wiley. Tidskriften inkluderar fr&auml;mst omr&aring;dena nya farmakologiska hypoteser, verkningsmekanism, identifiering av m&aring;lmolekyler och preklinisk och klinisk validering, l&auml;kemedelsuppt&auml;ckt, banbrytande uppt&auml;ckter inom translationell medicin samt replikationsstudier.<\/span><\/span><\/span><\/p>\n<p><span><span><span>Artikel: Sj&ouml;berg F, Waters S, L&ouml;fberg B, Sonesson C, Waters N, Tedroff J. A first-in-human oral dose study of mesdopetam (IRL790) to assess its safety, tolerability, and pharmacokinetics in healthy male volunteers. <em>Pharmacol Res Perspect.<\/em> 2021;9:e00792. <a href=\"https:\/\/doi.org\/10.1002\/prp2.792\">https:\/\/doi.org\/10.1002\/prp2.792<\/a>.<\/span><\/span><\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>IRLAB (Nasdaq Stockholm: IRLAB A) meddelade idag att en vetenskaplig artikel som beskriver resultaten f\u00f6r den kliniska fas I-studien med l\u00e4kemedelskandidaten mesdopetam har publicerats i tidskriften Pharmacology Research &amp; Perspectives (PR&amp;P). Mesdopetam \u00e4r en dopamin D3-receptorantagonist som nu utv\u00e4rderas i en internationell Fas IIb\/III-studie f\u00f6r behandling av levodopa-inducerade dyskinesier (LIDs) vid Parkinsons sjukdom.<\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[23],"tags":[],"class_list":["post-5831","post","type-post","status-publish","format-standard","hentry","category-pressmeddelande-2"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.7 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>IRLAB:s l\u00e4kemedelskandidat mesdopetams Fas I- resultat publicerade i vetenskapliga tidskriften PR&amp;P - IRLAB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/irlab.se\/sv\/irlabs-lakemedelskandidat-mesdopetams-fas-i-resultat-publicerade-i-vetenskapliga-tidskriften-prp\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"IRLAB:s l\u00e4kemedelskandidat mesdopetams Fas I- resultat publicerade i vetenskapliga tidskriften PR&amp;P - IRLAB\" \/>\n<meta property=\"og:description\" content=\"IRLAB (Nasdaq Stockholm: IRLAB A) meddelade idag att en vetenskaplig artikel som beskriver resultaten f\u00f6r den kliniska fas I-studien med l\u00e4kemedelskandidaten mesdopetam har publicerats i tidskriften Pharmacology Research &amp; Perspectives (PR&amp;P). Mesdopetam \u00e4r en dopamin D3-receptorantagonist som nu utv\u00e4rderas i en internationell Fas IIb\/III-studie f\u00f6r behandling av levodopa-inducerade dyskinesier (LIDs) vid Parkinsons sjukdom.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/irlab.se\/sv\/irlabs-lakemedelskandidat-mesdopetams-fas-i-resultat-publicerade-i-vetenskapliga-tidskriften-prp\/\" \/>\n<meta property=\"og:site_name\" content=\"IRLAB\" \/>\n<meta property=\"article:published_time\" content=\"2021-05-25T08:20:00+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minut\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/irlab.se\/sv\/irlabs-lakemedelskandidat-mesdopetams-fas-i-resultat-publicerade-i-vetenskapliga-tidskriften-prp\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/irlab.se\/sv\/irlabs-lakemedelskandidat-mesdopetams-fas-i-resultat-publicerade-i-vetenskapliga-tidskriften-prp\/\"},\"author\":{\"name\":\"\",\"@id\":\"\"},\"headline\":\"IRLAB:s l\u00e4kemedelskandidat mesdopetams Fas I- resultat publicerade i vetenskapliga tidskriften PR&amp;P\",\"datePublished\":\"2021-05-25T08:20:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/irlab.se\/sv\/irlabs-lakemedelskandidat-mesdopetams-fas-i-resultat-publicerade-i-vetenskapliga-tidskriften-prp\/\"},\"wordCount\":297,\"commentCount\":0,\"articleSection\":[\"Pressmeddelande\"],\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/irlab.se\/sv\/irlabs-lakemedelskandidat-mesdopetams-fas-i-resultat-publicerade-i-vetenskapliga-tidskriften-prp\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/irlab.se\/sv\/irlabs-lakemedelskandidat-mesdopetams-fas-i-resultat-publicerade-i-vetenskapliga-tidskriften-prp\/\",\"url\":\"https:\/\/irlab.se\/sv\/irlabs-lakemedelskandidat-mesdopetams-fas-i-resultat-publicerade-i-vetenskapliga-tidskriften-prp\/\",\"name\":\"IRLAB:s l\u00e4kemedelskandidat mesdopetams Fas I- resultat publicerade i vetenskapliga tidskriften PR&amp;P - IRLAB\",\"isPartOf\":{\"@id\":\"https:\/\/irlab.se\/#website\"},\"datePublished\":\"2021-05-25T08:20:00+00:00\",\"author\":{\"@id\":\"\"},\"breadcrumb\":{\"@id\":\"https:\/\/irlab.se\/sv\/irlabs-lakemedelskandidat-mesdopetams-fas-i-resultat-publicerade-i-vetenskapliga-tidskriften-prp\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/irlab.se\/sv\/irlabs-lakemedelskandidat-mesdopetams-fas-i-resultat-publicerade-i-vetenskapliga-tidskriften-prp\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/irlab.se\/sv\/irlabs-lakemedelskandidat-mesdopetams-fas-i-resultat-publicerade-i-vetenskapliga-tidskriften-prp\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/irlab.se\/sv\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"IRLAB:s l\u00e4kemedelskandidat mesdopetams Fas I- resultat publicerade i vetenskapliga tidskriften PR&amp;P\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/irlab.se\/#website\",\"url\":\"https:\/\/irlab.se\/\",\"name\":\"Irlab\",\"description\":\"Novel treatments for Parkinson&#039;s disease\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/irlab.se\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"IRLAB:s l\u00e4kemedelskandidat mesdopetams Fas I- resultat publicerade i vetenskapliga tidskriften PR&amp;P - IRLAB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/irlab.se\/sv\/irlabs-lakemedelskandidat-mesdopetams-fas-i-resultat-publicerade-i-vetenskapliga-tidskriften-prp\/","og_locale":"sv_SE","og_type":"article","og_title":"IRLAB:s l\u00e4kemedelskandidat mesdopetams Fas I- resultat publicerade i vetenskapliga tidskriften PR&amp;P - IRLAB","og_description":"IRLAB (Nasdaq Stockholm: IRLAB A) meddelade idag att en vetenskaplig artikel som beskriver resultaten f\u00f6r den kliniska fas I-studien med l\u00e4kemedelskandidaten mesdopetam har publicerats i tidskriften Pharmacology Research &amp; Perspectives (PR&amp;P). Mesdopetam \u00e4r en dopamin D3-receptorantagonist som nu utv\u00e4rderas i en internationell Fas IIb\/III-studie f\u00f6r behandling av levodopa-inducerade dyskinesier (LIDs) vid Parkinsons sjukdom.","og_url":"https:\/\/irlab.se\/sv\/irlabs-lakemedelskandidat-mesdopetams-fas-i-resultat-publicerade-i-vetenskapliga-tidskriften-prp\/","og_site_name":"IRLAB","article_published_time":"2021-05-25T08:20:00+00:00","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"1 minut"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/irlab.se\/sv\/irlabs-lakemedelskandidat-mesdopetams-fas-i-resultat-publicerade-i-vetenskapliga-tidskriften-prp\/#article","isPartOf":{"@id":"https:\/\/irlab.se\/sv\/irlabs-lakemedelskandidat-mesdopetams-fas-i-resultat-publicerade-i-vetenskapliga-tidskriften-prp\/"},"author":{"name":"","@id":""},"headline":"IRLAB:s l\u00e4kemedelskandidat mesdopetams Fas I- resultat publicerade i vetenskapliga tidskriften PR&amp;P","datePublished":"2021-05-25T08:20:00+00:00","mainEntityOfPage":{"@id":"https:\/\/irlab.se\/sv\/irlabs-lakemedelskandidat-mesdopetams-fas-i-resultat-publicerade-i-vetenskapliga-tidskriften-prp\/"},"wordCount":297,"commentCount":0,"articleSection":["Pressmeddelande"],"inLanguage":"sv-SE","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/irlab.se\/sv\/irlabs-lakemedelskandidat-mesdopetams-fas-i-resultat-publicerade-i-vetenskapliga-tidskriften-prp\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/irlab.se\/sv\/irlabs-lakemedelskandidat-mesdopetams-fas-i-resultat-publicerade-i-vetenskapliga-tidskriften-prp\/","url":"https:\/\/irlab.se\/sv\/irlabs-lakemedelskandidat-mesdopetams-fas-i-resultat-publicerade-i-vetenskapliga-tidskriften-prp\/","name":"IRLAB:s l\u00e4kemedelskandidat mesdopetams Fas I- resultat publicerade i vetenskapliga tidskriften PR&amp;P - IRLAB","isPartOf":{"@id":"https:\/\/irlab.se\/#website"},"datePublished":"2021-05-25T08:20:00+00:00","author":{"@id":""},"breadcrumb":{"@id":"https:\/\/irlab.se\/sv\/irlabs-lakemedelskandidat-mesdopetams-fas-i-resultat-publicerade-i-vetenskapliga-tidskriften-prp\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/irlab.se\/sv\/irlabs-lakemedelskandidat-mesdopetams-fas-i-resultat-publicerade-i-vetenskapliga-tidskriften-prp\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/irlab.se\/sv\/irlabs-lakemedelskandidat-mesdopetams-fas-i-resultat-publicerade-i-vetenskapliga-tidskriften-prp\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/irlab.se\/sv\/"},{"@type":"ListItem","position":2,"name":"IRLAB:s l\u00e4kemedelskandidat mesdopetams Fas I- resultat publicerade i vetenskapliga tidskriften PR&amp;P"}]},{"@type":"WebSite","@id":"https:\/\/irlab.se\/#website","url":"https:\/\/irlab.se\/","name":"Irlab","description":"Novel treatments for Parkinson&#039;s disease","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/irlab.se\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"}]}},"_links":{"self":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/posts\/5831","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/comments?post=5831"}],"version-history":[{"count":0,"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/posts\/5831\/revisions"}],"wp:attachment":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/media?parent=5831"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/categories?post=5831"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/tags?post=5831"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}